Biote Sees FY25 Revenue $202M-$208M Vs $227.18M Est.; Adj. EBITDA $59M-$64M
Author: Benzinga Newsdesk | March 13, 2025 09:48am
The Company expects the following for fiscal 2025:
($ in millions)
2025 Guidance Ranges
Revenue
$202-$208
Adjusted EBITDA2
$59-64
2025 Procedure revenue is expected to increase approximately 2-4% from 2024.
2025 Dietary supplements revenue is expected to increase approximately 5-10% from 2024.
Although we do not typically provide quarterly financial guidance, we expect first quarter 2025 revenue to be slightly higher as compared to the first quarter of 2024 as we ramp up training and onboarding of new practitioners to reinvigorate quickstart-related revenue. First quarter 2025 Adjusted EBITDA is expected to be approximately 5 percent lower as compared to the first quarter of 2024 due to increased sales and marketing activities to reaccelerate new customer growth.
